Skip to main content

Table 2 Univariate analyses of prognostic factors for 74 NSCLC patients with postoperative locoregional recurrence treated with radical radiotherapy

From: Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy

Variable

OS

PFS

LRFS

DMFS

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Age (≥ 59 vs. < 59 years)

1.387 (0.517–3.723)

0.516

0.532 (0.264–1.071)

0.077

0.789 (0.322–1.932)

0.604

0.619 (0.296–1.292)

0.201

Sex (male vs. female)

0.694 (0.197–2.443)

0.570

1.234 (0.603–2.527)

0.565

0.898 (0.324–2.492)

0.837

1.286 (0.605–2.735)

0.513

Stage of primary tumor (I vs. II vs. III)

1.308 (0.700–2.447)

0.400

1.173 (0.775–1.775)

0.451

1.084 (0.643–1.827)

0.762

1.189 (0.758–1.863)

0.451

Histology (squamous cell carcinoma vs. non-squamous cell carcinoma)

0.755 (0.261–2.183)

0.604

1.125 (0.510–2.482)

0.770

0.750 (0.270–2.085)

0.582

1.420 (0.582–3.466)

0.441

Recurrence site (stump vs. regional lymph nodes vs. ipsilateral lung vs. multiple sites)

1.292 (0.689–2.423)

0.425

1.284 (0.767–2.149)

0.342

1.439 (0.780–2.655)

0.245

1.433 (0.840–2.445)

0.187

Interval between surgery and recurrence (≥ 10 vs. < 10 months)

0.882 (0.328–2.373)

0.803

0.690 (0.352–1.351)

0.279

1.054 (0.434–2.559)

0.908

0.655 (0.320–1.339)

0.246

BED of radiation (≥ 78 vs. < 78 Gy)

0.347 (0.119–1.013)

0.053

0.905 (0.466–1.758)

0.769

0.288 (0.104–0.795)

0.016

1.075 (0.531–2.175)

0.841

Concurrent chemotherapy (yes vs. no)

1.222 (0.348–4.294)

0.754

1.114 (0.485–2.555)

0.799

1.247 (0.412–3.774)

0.696

1.150 (0.471–2.808)

0.758

EGFR status (wild-type vs. mutation type vs. unknown)

0.265 (0.063–1.112)

0.069

0.509 (0.238–1.088)

0.509

1.694 (0.465–6.175)

0.425

0.418 (0.192–0.912)

0.028

Radiation technique (3D-CRT vs. IMRT vs. SBRT)

2.562 (0.887–7.395)

0.082

1.213 (0.554–2.654)

0.630

2.047 (0.757–5.537)

0.158

1.130 (0.472–2.701)

0.784

GTV (≥ 28.7 vs. < 28.7 cm3)

1.864 (0.637–5.455)

0.256

1.246 (0.593–2.617)

0.561

0.543 (0.201–1.470)

0.230

1.525 (0.682–3.411)

0.304

  1. OS overall survival, PFS progression-free survival, LRFS local recurrence-free survival, DMFS distant metastasis-free survival, HR hazard ratio, CI confidence interval, BED biological effective dose, EGFR epidermal growth factor receptor, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, SBRT stereotactic body radiotherapy, GTV gross tumor volume